Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Faculdade Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Immunol Invest. 2022 May;51(4):883-898. doi: 10.1080/08820139.2021.1882486. Epub 2021 Feb 9.
Myocardial toxicity is a common side effect of doxorubicin (DOXO) therapy in breast cancer patients. We hypothesized that DOXO-induced cardiotoxicity may be related to the release of inflammatory cytokines in response to the treatment. This study aimed to assess changes in plasma levels of interleukin (IL)-1β, IL-6, IL-10 and tumor necrosis factor (TNF) after chemotherapy and to correlate these levels with cardiac biomarkers and clinical data.
Sixty-four patients with breast cancer treated with DOXO were included. Twenty-two subjects (cases) developed cardiotoxicity until one year after the end of DOXO treatment. Cytokines and cardiac markers were evaluated before starting chemotherapy (T0), up to 7 days after the last infusion (T1) and 12 months after the last infusion (T2).
Higher IL-10 levels were observed in the case group compared to controls at T1 ( = .006) and T2 ( = .046). The IL-1β, IL-6 and TNF levels did not change during treatment in each group ( > .05), nor between the case and control groups. The IL-10 levels were higher at T1 than at T0 and T2 ( < .05 for both) in the cardiotoxicity group. A correlation between IL-10 and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels at T0 and T2 in the cardiotoxicity group was observed ( = .048 and = .004, respectively).
Our study demonstrated that DOXO induced an increase in plasma IL-10 levels in patients who presented cardiotoxicity after treatment, which correlated with NT-proBNP levels.
多柔比星（DOXO）治疗乳腺癌患者会导致心肌毒性，这是一种常见的副作用。我们假设 DOXO 诱导的心肌毒性可能与治疗引起的炎症细胞因子释放有关。本研究旨在评估化疗后血浆白细胞介素（IL）-1β、IL-6、IL-10 和肿瘤坏死因子（TNF）水平的变化，并将这些水平与心脏生物标志物和临床数据相关联。
共纳入 64 例接受 DOXO 治疗的乳腺癌患者。22 例（病例组）在 DOXO 治疗结束后 1 年内发生了心脏毒性。在化疗前（T0）、最后一次输注后 7 天（T1）和最后一次输注后 12 个月（T2）评估细胞因子和心脏标志物。
与对照组相比，病例组在 T1（ = 0.006）和 T2（ = 0.046）时 IL-10 水平更高。在每组中，IL-1β、IL-6 和 TNF 水平在治疗期间均未发生变化（ > 0.05），病例组与对照组之间也无差异。在心脏毒性组中，T1 时的 IL-10 水平高于 T0 和 T2（T1 时均 < 0.05）。在心脏毒性组中，还观察到 T0 和 T2 时 IL-10 与 N 端脑钠肽前体（NT-proBNP）水平之间存在相关性（分别为 = 0.048 和 = 0.004）。
我们的研究表明，DOXO 治疗后出现心脏毒性的患者血浆 IL-10 水平升高，与 NT-proBNP 水平相关。
